

**Cigna Corporation**

**Quarterly Financial Supplement**  
**September 30, 2021**

*This document is dated November 4, 2021. The data contained in this document may not be accurate after such date and Cigna does not undertake to update or keep it accurate after such date.*



**Cigna Corporation**  
**September 30, 2021 Quarterly Financial Supplement**  
**Table of Contents**

<b>Financial Highlights</b> .....	<b>1</b>
<b>Consolidated Income Statements</b> .....	<b>2</b>
<b>Evernorth Segment Analysis</b> .....	<b>3</b>
<b>U.S. Medical Segment Analysis</b> .....	<b>5</b>
<b>International Markets Segment Analysis</b> .....	<b>9</b>
<b>Corporate and Other Operations Analysis</b> .....	<b>10</b>
<b>Consolidated Balance Sheets</b> .....	<b>11</b>
<b>Condensed Consolidated Statements of Cash Flows</b> .....	<b>12</b>

**BASIS OF PRESENTATION:**

*All dollar amounts are in millions, unless otherwise noted.*

*Cigna measures its financial results on a consolidated basis using adjusted income from operations and adjusted revenues. Adjusted income from operations and adjusted revenues on a consolidated basis are not determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be viewed as a substitute for the most directly comparable GAAP measures which are shareholders' net income and total revenues. Cigna also uses adjusted income from operations to measure the results of its segments, however the segment metric is determined before income taxes.*

*Adjusted income (loss) from operations is a principal financial measure of profitability used by Cigna's management because it presents the underlying results of operations of Cigna's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. The Company defines adjusted income from operations as shareholders' net income (or income before taxes for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the Financial Highlights page for a reconciliation of consolidated adjusted income from operations to shareholders' net income.*

*Adjusted revenues is used by Cigna's management because it permits analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the Financial Highlights page for a reconciliation of consolidated adjusted revenues to total revenues.*

*Beginning first quarter 2021, "Corporate and Other Operations" in this Quarterly Financial Supplement combines the results previously reported as "Corporate" and the segment previously reported as "Group Disability and Other". This change to simplify reporting was enabled by the sale of the Group Disability and Life business during the fourth quarter of 2020.*

*In some financial tables in this Quarterly Financial Supplement, we present percentage changes. When those changes are so large as to become not meaningful, we present "N/M" in place of the computed percentage.*

# Cigna Corporation

## Financial Highlights (unaudited)

(Dollars in millions, except per share amounts)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Total revenues</b>	\$ 44,288	\$ 40,955	8 %	\$ 128,390	\$ 118,689	8 %
Net realized investment results from certain equity method investments	22	(37)	N/M	12	(87)	N/M
Special item related to contractual adjustment for a former client	—	(117)	N/M	—	(204)	N/M
<b>Adjusted revenues</b>	\$ 44,310	\$ 40,801	9 %	\$ 128,402	\$ 118,398	8 %
<b>Shareholders' net income</b>	\$ 1,621	\$ 1,388	17	\$ 4,249	\$ 4,323	(2) %
<b>Pre-Tax Adjusted Income (Loss) From Operations by Segment</b>						
Evernorth	\$ 1,548	\$ 1,443	7 %	\$ 4,184	\$ 3,774	11 %
U.S. Medical	988	757	31	2,992	3,479	(14)
International Markets	250	208	20	746	809	(8)
Corporate and Other Operations	(275)	(296)	7	(936)	(892)	(5)
Consolidated pre-tax adjusted income from operations	\$ 2,511	\$ 2,112	19 %	\$ 6,986	\$ 7,170	(3) %
Adjusted income tax expense	575	494	16	1,578	1,642	(4)
<b>Consolidated after-tax adjusted income from operations</b>	\$ 1,936	\$ 1,618	20 %	\$ 5,408	\$ 5,528	(2) %
<b>Diluted earnings per share</b>						
<b>Shareholders' net income</b>	\$ 4.80	\$ 3.78	27 %	\$ 12.32	\$ 11.66	6 %
After-tax adjustments to reconcile to adjusted income from operations						
Net realized investment (gains) losses <sup>(1)</sup>	(0.12)	(0.17)		(0.29)	(0.20)	
Amortization of acquired intangible assets	1.15	1.02		3.40	2.86	
<b>Special items</b>						
Debt extinguishment costs	—	—		0.32	0.41	
Integration and transaction-related (benefits) costs	(0.10)	0.23		—	0.69	
(Benefits) charges associated with litigation matters	—	—		(0.06)	0.05	
Charge for organizational efficiency plan	—	—		—	0.06	
Risk corridors recovery	—	(0.21)		—	(0.20)	
Contractual adjustment for a former client	—	(0.24)		—	(0.42)	
<b>Total special items</b>	<b>(0.10)</b>	<b>(0.22)</b>		<b>0.26</b>	<b>0.59</b>	
<b>Adjusted income from operations</b>	\$ 5.73	\$ 4.41	30 %	\$ 15.69	\$ 14.91	5 %
Weighted average shares (in thousands)	337,579	367,190		344,780	370,831	
<b>Adjusted EBITDA <sup>(2)</sup></b>	\$ 3,049	\$ 2,657	15 %	\$ 8,588	\$ 8,876	(3) %
<b>Operating cash flow (see page 12)</b>	2,119	895	137 %	2,916	6,056	(52) %
<b>SG&amp;A expense ratio <sup>(3)</sup></b>	7.0 %	8.1 %	110 bps	7.3 %	8.3 %	100 bps

### CUSTOMER RELATIONSHIPS

(Relationships, lives and policies in thousands)

	As of September 30,			As of December 31,	
	2021	2020	% Change	2020	% Change
Pharmacy <sup>(4)</sup>	103,612	97,495	6 %	98,850	5 %
Medical (see page 7)	17,041	16,982	—	16,673	2
Behavioral Care	39,784	37,236	7	36,908	8
Dental	17,753	17,671	—	17,542	1
Medicare Part D	3,184	3,296	(3)	3,291	(3)
International Markets policies	12,259	12,013	2	12,111	1
<b>Total customer relationships <sup>(5)</sup></b>	<b>193,633</b>	<b>184,693</b>	<b>5 %</b>	<b>185,375</b>	<b>4 %</b>

(1) Includes the Company's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting.

(2) Adjusted income from operations excluding interest, taxes, depreciation and amortization ("Adjusted EBITDA") is a non-GAAP measure, defined as shareholders' net income excluding income taxes and the before-tax impact of special items, interest expense, total depreciation and amortization, and net realized investment results.

(3) SG&A expense ratio is calculated as follows: Cigna's total selling, general and administrative expenses excluding special items divided by Cigna's consolidated adjusted revenues

(4) Effective January 1, 2021, Pharmacy lives have been updated to reflect actual eligibility data for benefits provided to Prime Therapeutics. Previously these lives had been estimated based on prescriptions filled during the period. Pharmacy lives for prior periods have been restated to reflect this change.

(5) Covered lives associated with the Group Disability and Life business that was sold on December 31, 2020 have been excluded from this table.

**Cigna Corporation**  
**Consolidated Income Statements (unaudited)**

(Dollars in millions)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Revenues</b>						
Pharmacy revenues	\$ 31,013	\$ 27,802	12 %	\$ 89,085	\$ 79,464	12 %
Premiums	10,275	10,682	(4)	30,812	31,928	(3)
Fees and other revenues	2,532	2,174	16	7,324	6,424	14
Net investment income	468	297	58	1,169	873	34
Total revenues	44,288	40,955	8	128,390	118,689	8
<b>Benefits and expenses</b>						
Pharmacy and other service costs	30,070	26,624	13	86,306	76,425	13
Medical costs and other benefit expenses	8,330	8,429	(1)	24,819	23,863	4
Selling, general and administrative expenses excluding special items	3,080	3,290	(6)	9,337	9,812	(5)
Amortization of acquired intangible assets	501	493	2	1,499	1,487	1
Special items	13	11	18	31	294	(89)
Total benefits and expenses	41,994	38,847	8	121,992	111,881	9
<b>Income from operations</b>						
	2,294	2,108	9	6,398	6,808	(6)
Interest expense and other	(303)	(336)	10	(915)	(1,101)	17
Debt extinguishment costs	—	—	N/M	(141)	(199)	29
Net realized investment gains (losses)	68	32	113	128	(18)	N/M
<b>Income before income taxes</b>	2,059	1,804	14	5,470	5,490	—
Total income taxes	424	406	4	1,188	1,143	4
<b>Net income</b>	1,635	1,398	17	4,282	4,347	(1)
Less: Net income attributable to noncontrolling interests	14	10	40	33	24	38
<b>Shareholders' net income</b>	1,621	1,388	17	4,249	4,323	(2)
<b>After-tax adjustments to reconcile adjusted income from operations</b>						
Net realized investment (gains) losses <sup>(1)</sup>	(42)	(64)		(99)	(75)	
Amortization of acquired intangible assets	392	376		1,168	1,061	
<b>Special items</b>						
Debt extinguishment costs	—	—		110	151	
Integration and transaction-related (benefits) costs	(35)	83		1	256	
(Benefits) charges associated with litigation matters	—	—		(21)	19	
Charge for organizational efficiency plan	—	—		—	24	
Risk corridors recovery	—	(76)		—	(76)	
Contractual adjustment for a former client	—	(89)		—	(155)	
<b>Adjusted income from operations</b>	\$ 1,936	\$ 1,618	20 %	\$ 5,408	\$ 5,528	(2) %

(1) Includes the Company's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting.

**Cigna Corporation**  
**Evernorth**  
**Segment Results (unaudited)**

(Dollars in millions)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Revenues</b>						
Pharmacy revenues	\$ 31,985	\$ 28,750	11 %	\$ 92,411	\$ 82,440	12 %
Fees and other revenues	1,625	1,192	36	4,403	3,331	32
Net investment income	4	2	100	12	30	(60)
Total revenues	33,614	29,944	12	96,826	85,801	13
<b>Benefits and expenses</b>						
Pharmacy and other service costs	31,453	27,837	13	90,747	80,212	13
Gross profit	2,161	2,107	3	6,079	5,589	9
Selling, general and administrative expenses	603	542	11	1,873	1,598	17
Amortization of acquired intangible assets	484	479	1	1,449	1,439	1
<b>Income from operations</b>	1,074	1,086	(1)	2,757	2,552	8
Interest expense and other	—	—	N/M	(1)	(1)	—
Net realized investment gains (losses)	—	—	N/M	(4)	—	N/M
<b>Income before income taxes</b>	1,074	1,086	(1)	2,752	2,551	8
<b>Pre-tax adjustments required to reconcile to adjusted income from operations</b>						
Pre-tax (income) attributable to noncontrolling interests	(10)	(5)		(21)	(12)	
Net realized investment (gains) losses	—	—		4	—	
Amortization of acquired intangible assets	484	479		1,449	1,439	
Special items	—	(117)		—	(204)	
<b>Pre-tax adjusted income from operations</b>	\$ 1,548	\$ 1,443	7 %	\$ 4,184	\$ 3,774	11 %
<b>Pre-tax adjusted margin</b>	4.6 %	4.8 %	(20) bps	4.3 %	4.4 %	(10) bps
<b>Reconciliation of total revenues to adjusted revenues</b>						
Total revenues	\$ 33,614	\$ 29,944	12 %	\$ 96,826	\$ 85,801	13 %
Special item related to contractual adjustment for a former client	—	(117)	N/M	—	(204)	N/M
Adjusted revenues	\$ 33,614	\$ 29,827	13 %	\$ 96,826	\$ 85,597	13 %

**Cigna Corporation**  
**Evernorth**  
**Key Metrics (unaudited)**

*(Dollars and adjusted scripts in millions)*

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Selected Financial Information <sup>(1)</sup></b>						
Adjusted EBITDA <sup>(2)</sup>	\$ 1,643	\$ 1,522	8 %	\$ 4,456	\$ 4,007	11 %
<b>Pharmacy revenue by distribution channel <sup>(1)</sup></b>						
Adjusted network revenues	\$ 16,488	\$ 14,522	14	\$ 47,792	\$ 41,179	16
Adjusted home delivery and specialty revenues	13,796	12,699	9	39,911	37,111	8
Other revenues	1,701	1,412	20	4,708	3,946	19
Total adjusted pharmacy revenues	\$ 31,985	\$ 28,633	12	\$ 92,411	\$ 82,236	12
<b>Pharmacy script volume</b>						
Adjusted network scripts <sup>(3)</sup>	340	309	10	1,002	890	13
Adjusted home delivery and specialty scripts <sup>(3)</sup>	71	72	(1)	212	215	(1)
Total adjusted scripts <sup>(3)</sup>	411	381	8 %	1,214	1,105	10 %
<b>Generic fill rate</b>						
Network	86.3 %	87.0 %		86.3 %	87.9 %	
Home delivery	85.9 %	85.3 %		85.8 %	85.1 %	
Overall generic fill rate	86.3 %	86.9 %		86.3 %	87.6 %	

(1) Evernorth segment metrics on this page are presented excluding special items.

(2) Adjusted income from operations excluding interest, taxes, depreciation and amortization ("Adjusted EBITDA") is a non-GAAP measure, defined as shareholders' net income excluding income taxes and the before-tax impact of special items, interest expense, total depreciation and amortization, and net realized investment results.

(3) Non-specialty network scripts filled through 90-day programs, and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.

**Cigna Corporation**  
**U.S. Medical**  
**Segment Results (unaudited)**

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<i>(Dollars in millions)</i>						
<b>Revenues</b>						
Premiums	\$ 8,771	\$ 8,196	7 %	\$ 26,311	\$ 24,428	8 %
Fees and other revenues	1,404	1,329	6	4,260	4,019	6
Net investment income	322	104	210	744	279	167
Total revenues <sup>(1)</sup>	10,497	9,629	9	31,315	28,726	9
<b>Benefits and expenses</b>						
Medical costs	7,399	6,769	9	22,068	18,863	17
Selling, general and administrative expenses	2,110	2,103	—	6,255	6,384	(2)
Amortization of acquired intangible assets	6	6	—	20	23	(13)
Special items	—	(101)	N/M	—	(101)	N/M
Total benefits and expenses	9,515	8,777	8	28,343	25,169	13
<b>Income from operations</b>	982	852	15	2,972	3,557	(16)
Net realized investment gains (losses)	93	(6)	N/M	172	(28)	N/M
<b>Income before income taxes</b>	1,075	846	27	3,144	3,529	(11)
<b>Pre-tax adjustments required to reconcile to adjusted income from operations</b>						
Net realized investment (gains) losses	(93)	6		(172)	28	
Amortization of acquired intangible assets	6	6		20	23	
Special items	—	(101)		—	(101)	
<b>Pre-tax adjusted income from operations</b>	\$ 988	\$ 757	31 %	\$ 2,992	\$ 3,479	(14) %
<b>Pre-tax adjusted margin</b>	9.4 %	7.9 %	150 bps	9.6 %	12.1 %	(250) bps

(1) Total revenues were equal to adjusted revenues in the U.S. Medical segment for the periods presented.

**Cigna Corporation**  
**U.S. Medical**  
**Revenue and Medical Care Ratio (unaudited)**

(Dollars in millions)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Premiums:</b>						
<b>U.S. Commercial Premiums</b>						
Risk	\$ 3,591	\$ 3,397	6 %	\$ 10,692	\$ 9,948	7 %
Stop loss	1,225	1,146	7	3,613	3,459	4
Other	320	281	14	938	853	10
Total U.S. Commercial premiums	<u>5,136</u>	<u>4,824</u>	6	<u>15,243</u>	<u>14,260</u>	7
<b>U.S. Government Premiums</b>						
Medicare Advantage	2,079	1,895	10	6,287	5,680	11
Medicare Part D	315	360	(13)	1,175	1,242	(5)
Other	1,241	1,117	11	3,606	3,246	11
Total U.S. Government premiums	<u>3,635</u>	<u>3,372</u>	8	<u>11,068</u>	<u>10,168</u>	9
Total premiums	8,771	8,196	7	26,311	24,428	8
Fees and other revenues	1,404	1,329	6	4,260	4,019	6
Net investment income	322	104	210	744	279	167
<b>Total revenues</b>	<b>\$ 10,497</b>	<b>\$ 9,629</b>	<b>9 %</b>	<b>\$ 31,315</b>	<b>\$ 28,726</b>	<b>9 %</b>
<b>Medical Care Ratio</b>	<b>84.4 %</b>	<b>82.6 %</b>	<b>(180) bps</b>	<b>83.9 %</b>	<b>77.2 %</b>	<b>(670) bps</b>



**Cigna Corporation**  
**Total Medical Customers (unaudited)**

COVERED LIVES BY FUNDING TYPE:	As of September 30,			As of December 31,			COVERED LIVES BY MARKET SEGMENT: <sup>(5)</sup>	As of September 30,			As of December 31,	
	2021	2020	% Change	2020	% Change	2021		2020 <sup>(6)</sup>	% Change	2020 <sup>(6)</sup>	% Change	
<i>(Lives in thousands)</i>						<i>(Lives in thousands)</i>						
<b>Medical customers: <sup>(1)</sup></b>						<b>Medical customers: <sup>(1)</sup></b>						
U.S. Commercial risk	2,135	2,120	1 %	2,141	— %	National Accounts	3,268	3,425	(5) %	3,392	(4) %	
U.S. Government risk						Middle Market	7,947	8,055	(1)	7,778	2	
Medicare Advantage	567	523	8	525	8	Select	2,564	2,420	6	2,454	4	
Individual <sup>(2)</sup>	378	277	36	258	47	Small	9	1	N/M	2	N/M	
Other <sup>(3)</sup>	572	613	(7)	604	(5)	Total U.S. Commercial	13,788	13,901	(1)	13,626	1	
Total U.S. Government risk	1,517	1,413	7	1,387	9	Total U.S. Government	1,517	1,413	7	1,387	9	
Services only customers - U.S. Medical	11,653	11,781	(1)	11,485	1	Total U.S. Medical	15,305	15,314	—	15,013	2	
Total U.S. Medical	15,305	15,314	—	15,013	2	International Markets	1,736	1,668	4	1,660	5	
International Markets <sup>(4)</sup>	1,736	1,668	4	1,660	5							
<b>Total medical customers</b>	<b>17,041</b>	<b>16,982</b>	<b>— %</b>	<b>16,673</b>	<b>2 %</b>	<b>Total medical customers</b>	<b>17,041</b>	<b>16,982</b>	<b>— %</b>	<b>16,673</b>	<b>2 %</b>	

(1) Includes individuals in our U.S. Medical and International Markets segments who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna; have access to Cigna's provider network for covered services under their medical plan; or have medical claims and services that are administered by Cigna.

(2) As of September 30, 2021, individual business includes on-exchange Patient Protection and Affordable Care and Education Reconciliation Act ("ACA") business (367,000 customers) and off-exchange ACA business (11,000 customers). We exited the off-exchange non-ACA business effective January 1, 2021.

(3) Includes Medicaid and Medicare Supplement customers.

(4) International Markets medical customers excludes medical customers served by less than 100% owned subsidiaries.

(5) Market Segments are defined as follows:

~ the National Accounts market segment includes multi-state employers with more than 5,000 U.S. based, full-time employees in more than one state

~ the Middle Market segment includes employers with more than 500 but fewer than 5,000 U.S. based, full-time employees, single-site employers with more than 5,000 employees, Taft Hartley plans, and other third party payers;

~ the Select market segment includes employers with more than 50 but fewer than 500 eligible employees;

~ the Small market segment includes employers with 2-50 employees.

~ the U.S. Government market segment offers Medicare Advantage (both to individuals who are post-65 retirees, as well as employer group sponsored pre- and post-65 retirees), Prescription Drug Program, Medicare Supplement and Medicaid products as managed care alternatives to publicly funded healthcare programs. The segment also offers individual health insurance coverage both on and off the public exchanges.

~ the International Markets segment is focused on health care and supplemental products and services to meet the needs of local and multinational individuals and organizations and their local and globally mobile employees and dependents.

(6) Prior year lives have been reclassified to reflect current market segment presentation at the employer level, according to the definitions discussed in note 5.

**Cigna Corporation**  
**U.S. Medical**  
**Unpaid Claims Liability (unaudited)**

*(Dollars in millions)*

	Nine Months Ended September 30,		Year Ended
	2021	2020	December 31, 2020
Beginning balance	\$ 3,184	\$ 2,892	\$ 2,892
Less: Reinsurance and other amounts recoverable	224	303	303
Beginning balance, net	2,960	2,589	2,589
<b>Incurred costs related to:</b>			
Current year	22,167	18,935	25,889
Prior years	(180)	(126)	(115)
Total incurred	21,987	18,809	25,774
<b>Paid costs related to:</b>			
Current year	18,701	16,061	23,005
Prior years	2,665	2,363	2,398
Total paid	21,366	18,424	25,403
Ending balance, net	3,581	2,974	2,960
Add: Reinsurance and other amounts recoverable	265	226	224
Ending balance <sup>(1)</sup>	\$ 3,846	\$ 3,200	\$ 3,184

(1) The ending balance is included in the Insurance and contractholder liabilities balance on the Consolidated Balance Sheets. For additional information regarding this liability, see the Insurance and Contractholder Liabilities footnote in Cigna's Form 10-Q for the period ended September 30, 2021, expected to be filed on November 4, 2021.

**Cigna Corporation**  
**International Markets**  
**Segment Results (unaudited)**

(Dollars in millions)

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<b>Revenues</b>						
Premiums	\$ 1,446	\$ 1,360	6 %	\$ 4,338	\$ 4,079	6 %
Fees and other revenues	54	79	(32)	188	246	(24)
Net investment income	66	38	74	180	104	73
Total revenues	1,566	1,477	6	4,706	4,429	6
<b>Benefits and expenses</b>						
Medical costs and other benefit expenses	881	780	13	2,601	2,246	16
Selling, general and administrative expenses <sup>(1)</sup>	454	451	1	1,362	1,282	6
Amortization of acquired intangible assets	11	8	38	30	22	36
Total benefits and expenses	1,346	1,239	9	3,993	3,550	12
<b>Income from operations</b>	220	238	(8)	713	879	(19)
Interest expense and other	3	4	(25)	9	10	(10)
Net realized investment gains (losses)	(24)	11	N/M	(37)	(12)	(208)
<b>Income before income taxes</b>	199	253	(21)	685	877	(22)
<b>Pre-tax adjustments required to reconcile adjusted income from operations</b>						
Pre-tax (income) attributable to noncontrolling interests	(6)	(5)		(18)	(15)	
Net realized investment (gains) losses	46	(48)		49	(75)	
Amortization of acquired intangible assets	11	8		30	22	
<b>Pre-tax adjusted income from operations</b>	\$ 250	\$ 208	20 %	\$ 746	\$ 809	(8) %
<b>Pre-tax adjusted margin</b>	15.7 %	14.4 %	130 bps	15.8 %	18.6 %	(280) bps
<b>Reconciliation of total revenues to adjusted revenues</b>						
Total revenues	\$ 1,566	\$ 1,477	6 %	\$ 4,706	\$ 4,429	6 %
Net realized investment results from certain equity method investments	22	(37)	N/M	12	(87)	N/M
Adjusted revenues	\$ 1,588	\$ 1,440	10 %	\$ 4,718	\$ 4,342	9 %

(1) Selling, general and administrative expenses include policy acquisition expenses of \$178 million for the three months ended and \$523 million for the nine months ended September 30, 2021 and \$170 million for the three months ended and \$472 million for the nine months ended September 30, 2020.

**Cigna Corporation**  
**Corporate and Other Operations**  
**Results (unaudited)**

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2021	2020	% Change	2021	2020	% Change
<i>(Dollars in millions)</i>						
<b>Revenues</b>						
Total revenues and eliminations <sup>(1)</sup>	\$ (1,389)	\$ (95)	N/M %	\$ (4,457)	\$ (267)	N/M %
<b>Expenses</b>						
Total expenses and eliminations excluding special items	(1,420)	(139)	N/M	(4,444)	(482)	N/M
Special items	13	112	(88)	31	395	(92)
Total expenses and eliminations	(1,407)	(27)	N/M	(4,413)	(87)	N/M
<b>Loss from operations</b>	18	(68)	N/M	(44)	(180)	76
Interest expense and other	(306)	(340)	10	(923)	(1,110)	17
Debt extinguishment costs	—	—	N/M	(141)	(199)	29
Net realized investment gains (losses)	(1)	27	N/M	(3)	22	N/M
<b>Loss before income taxes</b>	(289)	(381)	24	(1,111)	(1,467)	24
<b>Pre-tax adjustments required to reconcile adjusted income (loss) from operations</b>						
Net realized investment (gains) losses	1	(27)		3	(22)	
Amortization of acquired intangible assets	—	—		—	3	
Special items	13	112		172	594	
<b>Pre-tax adjusted loss from operations</b>	\$ (275)	\$ (296)	7 %	\$ (936)	\$ (892)	(5) %

Beginning first quarter 2021, "Corporate and Other Operations" in this Quarterly Financial Supplement combines the results previously reported as "Corporate" and the segment previously reported as "Group Disability and Other". This change to simplify reporting was enabled by the sale of the Group Disability and Life business during the fourth quarter of 2020.

(1) Includes amounts for elimination of intercompany revenues and expenses. Total revenues were equal to adjusted revenues in Corporate and Other Operations for the periods presented.

**Cigna Corporation**  
**Consolidated Balance Sheets (unaudited)**

(Dollars in millions)

	As of September 30, 2021	As of December 31, 2020		As of September 30, 2021	As of December 31, 2020
<b>Assets</b>			<b>Liabilities</b>		
<b>Current Assets</b>			<b>Current Liabilities</b>		
Cash and cash equivalents	\$ 3,483	\$ 10,182	Current insurance and contractholder liabilities	\$ 5,917	\$ 5,308
Investments	1,374	1,331	Pharmacy and other service costs payable	14,705	13,347
Accounts receivable, net	16,250	12,191	Accounts payable	5,659	5,478
Inventories	3,020	3,165	Accrued expenses	7,356	8,515
Other current assets	1,360	930	Short-term debt and current maturities of long-term debt	2,703	3,374
Total current assets	25,487	27,799	Total current liabilities	36,340	36,022
Long-term investments	23,756	23,262	Non-current insurance and contractholder liabilities	16,576	16,844
Reinsurance recoverables <sup>(1)</sup>	5,035	5,200	Deferred tax liabilities, net	8,832	8,939
Deferred policy acquisition costs	3,367	3,385	Other non-current liabilities	4,261	4,629
Property and equipment	4,070	4,205	Long-term debt	31,609	29,545
Goodwill	46,056	44,648	Separate account liabilities	9,150	9,086
Other intangibles	34,615	35,179	Total liabilities	106,768	105,065
Other assets	2,715	2,687			
Separate account assets	9,150	9,086	Redeemable noncontrolling interests	56	58
			<b>Shareholders' Equity</b>		
			Common stock	4	4
			Additional paid-in capital	29,077	28,975
			Accumulated other comprehensive (loss)	(1,153)	(861)
			Retained earnings	31,803	28,575
			Less treasury stock, at cost	(12,316)	(6,372)
			Total shareholders' equity	47,415	50,321
			Other noncontrolling interests	12	7
			Total equity	47,427	50,328
Total assets	\$ 154,251	\$ 155,451	Total liabilities and equity	\$ 154,251	\$ 155,451

(1) Includes \$4.62 billion as of September 30, 2021 and \$4.92 billion as of December 31, 2020 related to: 1) the sale of Cigna's Individual Life & Annuity business in 1998 and Cigna's Retirement Benefits business in 2004, which were primarily in the form of reinsurance arrangements; 2) the reinsurance transaction with Berkshire in 2013; and 3) the sale of Cigna's Group Disability and Life business to New York Life in 2020. Corresponding liabilities are primarily reported in Insurance and contractholder liabilities.

**Cigna Corporation**  
**Condensed Consolidated Statements of Cash Flows (unaudited)**

(Dollars in millions)

	Nine Months Ended September 30,	
	2021	2020
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net income	\$ 4,282	\$ 4,347
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,180	2,089
Realized investment (gains) losses, net	(128)	18
Deferred income tax (benefit)	(104)	(340)
Debt extinguishment costs	141	199
<b>Net changes in assets and liabilities, net of non-operating effects:</b>		
Accounts receivable	(4,039)	(2,810)
Inventories	145	5
Deferred policy acquisition costs	(182)	(244)
Reinsurance recoverable and other assets	(281)	(468)
Insurance liabilities	863	740
Pharmacy costs and other service costs payable	1,357	2,084
Accounts payable and accrued expenses and other liabilities	(1,411)	(32)
Other, net	93	468
<b>Net cash provided by operating activities</b>	<u>2,916</u>	<u>6,056</u>
<b>Net cash (used in) investing activities</b>	(3,734)	(1,444)
<b>Net cash (used in) financing activities <sup>(1)</sup></b>	(5,841)	(3,812)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash	(46)	(7)
<b>Net (decrease) increase in cash, cash equivalents and restricted cash</b>	(6,705)	793
Cash, cash equivalents, and restricted cash January 1, <sup>(2)</sup>	10,245	5,411
Cash, cash equivalents and restricted cash September 30,	\$ 3,540	\$ 6,204
Cash reclassified to assets held for sale	—	(798)
<b>Cash, cash equivalents, and restricted cash September 30, per Consolidated Balance Sheets <sup>(3)</sup></b>	<u>\$ 3,540</u>	<u>\$ 5,406</u>

(1) Includes \$6.3 billion for stock repurchases, \$4.7 billion for the repayment and extinguishment of long term debt, offset by \$4.3 billion for the issuance of long term debt and \$1.7 billion borrowing of commercial paper for the nine months ended September 30, 2021.

(2) Includes restricted cash of \$26 million reported in Other noncurrent assets and \$23 million reported in Long-term investments, and \$743 million cash reported in Assets held for sale as of January 1, 2020.

(3) Includes restricted cash of \$57 million reported in Long-term investments as of September 30, 2021.